Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Leucanthemum vulgare pollen is an allergenic extract derived from the pollen of the oxeye daisy (*Leucanthemum vulgare*). Developed and distributed by Greer Laboratories, it is used primarily as a diagnostic tool in allergy testing to identify hypersensitivity to daisy pollen. The product is formulated as a non-standardized allergenic solution for intradermal, percutaneous, or subcutaneous administration. Its mechanism of action involves exposing the patient's immune system to specific allergens, which triggers a measurable IgE-mediated response (such as a wheal-and-flare reaction) in sensitized individuals, thereby confirming an allergy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Leucanthemum vulgare pollen.